News - Page 129 - Psychedelic Alpha

Our 🎯 Q1 2026 Psychedelic Pipeline Bullseye Charts are now available.

Read more about the article MYND Life Sciences Announces Collaborative Research Agreement with the University of British Columbia

MYND Life Sciences Announces Collaborative Research Agreement with the University of British Columbia

Post published:January 12, 2022
Post category:Press Release

Read more about the article atai Life Sciences announces FDA Investigational New Drug (IND) Clearance for PCN-101 R-ketamine Program

atai Life Sciences announces FDA Investigational New Drug (IND) Clearance for PCN-101 R-ketamine Program

Post published:January 12, 2022
Post category:Press Release

Read more about the article PharmaTher Announces FDA Approval of Investigational New Drug (IND) Application for Ketamine to Treat ALS

PharmaTher Announces FDA Approval of Investigational New Drug (IND) Application for Ketamine to Treat ALS

Post published:January 12, 2022
Post category:Press Release

Read more about the article Wesana Health Provides Strategic and Operational Updates

Wesana Health Provides Strategic and Operational Updates

Post published:January 12, 2022
Post category:Press Release

Read more about the article Field Trip Receives Notice of Allowance for US Patent Application Covering FT-104 (Isoprocin Glutarate), its Novel Psychedelic Molecule in Development

Field Trip Receives Notice of Allowance for US Patent Application Covering FT-104 (Isoprocin Glutarate), its Novel Psychedelic Molecule in Development

Post published:January 11, 2022
Post category:Press Release

Read more about the article Wesana Health Granted US FDA Pre-IND Meeting for SANA-013

Wesana Health Granted US FDA Pre-IND Meeting for SANA-013

Post published:January 11, 2022
Post category:Press Release

Read more about the article Institutional Review Board Grants Approval for Cybin-Sponsored Feasibility Study Using Kernel Flow Technology to Measure Psychedelic Effects on the Brain

Institutional Review Board Grants Approval for Cybin-Sponsored Feasibility Study Using Kernel Flow Technology to Measure Psychedelic Effects on the Brain

Post published:January 11, 2022
Post category:Press Release

Read more about the article Awakn Life Sciences Announces Positive Results from Phase II A/B Ketamine-Assisted Therapy for Treatment of Alcohol Use Disorder Trial

Awakn Life Sciences Announces Positive Results from Phase II A/B Ketamine-Assisted Therapy for Treatment of Alcohol Use Disorder Trial

Post published:January 11, 2022
Post category:Press Release

Read more about the article Psychedelic Research and Clinical Trials in 2021

Psychedelic Research and Clinical Trials in 2021

Post published:January 10, 2022
Post category:Analysis

Read more about the article Mydecine Achieves Innovative Supercomputing Artificial Intelligence Modeling in Psychedelic Drug Development Enabling Quick Screening of Billions of Compounds

Mydecine Achieves Innovative Supercomputing Artificial Intelligence Modeling in Psychedelic Drug Development Enabling Quick Screening of Billions of Compounds

Post published:January 10, 2022
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond. Psy Alpha Ltd is a company registered in England and Wales (16989109).

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.